King Pharmaceuticals and partner Acura Pharmaceuticals recently announced the submission of a new drug application for their opioid candidate, Acurox, according to a Zacks Investment Research report.
The companies are seeking FDA approval for the use of Acurox to provide relief from moderate to severe pain. Earlier this year, the FDA panel voted it did not have sufficient evidence to support the approval of Acurox for these conditions.
King Pharmaceuticals intends to provide an update on the regulatory status of Acurox soon, according to the report.
Read the Zacks Investment Research report on Acurox.
Read more on spine care and pain management:
-4 Steps for Successful Orthopedic Surgeon Recruitment
-Practical Guidance for Containing Orthopedic Device Costs
-3 Ways Ravine Surgery Center Increased Spine Case Volume
The companies are seeking FDA approval for the use of Acurox to provide relief from moderate to severe pain. Earlier this year, the FDA panel voted it did not have sufficient evidence to support the approval of Acurox for these conditions.
King Pharmaceuticals intends to provide an update on the regulatory status of Acurox soon, according to the report.
Read the Zacks Investment Research report on Acurox.
Read more on spine care and pain management:
-4 Steps for Successful Orthopedic Surgeon Recruitment
-Practical Guidance for Containing Orthopedic Device Costs
-3 Ways Ravine Surgery Center Increased Spine Case Volume